Literature DB >> 11377918

Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve.

I Sora1, G Elmer, M Funada, J Pieper, X F Li, F S Hall, G R Uhl.   

Abstract

Homozygous transgenic knockout mice without mu-opioid receptors lack morphine-induced antinociception, locomotion, tolerance, physical dependence, and reward. mu receptors thus appear to play central roles in these morphine actions. Different levels of mu receptor expression are found in different humans and in different animal strains. In vitro studies indicate that some morphine responses persist after inactivation of as many as 90% of the initial mu receptor complement, while others are attenuated after inactivating many fewer receptors. Varying levels of mu receptor reserve could thus exist in different mu-expressing neuronal populations in vivo. Heterozygous mu receptor knockout mice express half of wild-type mu receptor levels. Tests of morphine actions in these mice reveal evidence for differing mu receptor reserves in brain circuits that mediate distinct opiate effects. Heterozygotes display attenuated locomotion, reduced morphine self-administration, intact tolerance, rightward shifts in morphine lethality dose/effect relationships, and variable effects on place preference compared to wild-type mice. They demonstrate full physical dependence, as measured by naloxone-precipitated abstinence following five days of morphine administration. Neuroadaptive changes in sites other than mu receptors could be involved in some of these results. Nevertheless, these data document substantial influences that individual differences in levels of mu receptor expression could exert on distinct opiate drug effects. They support the idea that functional mu receptor reserve differs among the diverse neuronal populations that mediate distinct properties of opiate drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377918     DOI: 10.1016/S0893-133X(00)00252-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  44 in total

Review 1.  Non-nociceptive roles of opioids in the CNS: opioids' effects on neurogenesis, learning, memory and affect.

Authors:  Cherkaouia Kibaly; Chi Xu; Catherine M Cahill; Christopher J Evans; Ping-Yee Law
Journal:  Nat Rev Neurosci       Date:  2019-01       Impact factor: 34.870

2.  Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers.

Authors:  Katarina Drakenberg; Andrej Nikoshkov; Monika Cs Horváth; Pernilla Fagergren; Anna Gharibyan; Kati Saarelainen; Sadia Rahman; Ingrid Nylander; Georgy Bakalkin; Jovan Rajs; Eva Keller; Yasmin L Hurd
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

3.  Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin.

Authors:  Y Zhang; M Landthaler; S D Schlussman; V Yuferov; A Ho; T Tuschl; M J Kreek
Journal:  Neuroscience       Date:  2008-10-02       Impact factor: 3.590

Review 4.  The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?

Authors:  Ji Hoon Yoo; Ian Kitchen; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

5.  Qualitative differences between C57BL/6J and DBA/2J mice in morphine potentiation of brain stimulation reward and intravenous self-administration.

Authors:  Greg I Elmer; Jeanne O Pieper; Lindsey R Hamilton; Roy A Wise
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

Review 6.  Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal.

Authors:  Nobue Kitanaka; Junichi Kitanaka; F Scott Hall; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura; Xiao-Bing Wang; George R Uhl
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

Review 7.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

8.  OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.

Authors:  Gabor Oroszi; Raymond F Anton; Stephanie O'Malley; Robert Swift; Helen Pettinati; David Couper; Qiaoping Yuan; David Goldman
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

9.  Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food.

Authors:  Pauline Charbogne; Olivier Gardon; Elena Martín-García; Helen L Keyworth; Aya Matsui; Anna E Mechling; Thomas Bienert; Md Taufiq Nasseef; Anne Robé; Luc Moquin; Emmanuel Darcq; Sami Ben Hamida; Patricia Robledo; Audrey Matifas; Katia Befort; Claire Gavériaux-Ruff; Laura-Adela Harsan; Dominik von Elverfeldt; Jurgen Hennig; Alain Gratton; Ian Kitchen; Alexis Bailey; Veronica A Alvarez; Rafael Maldonado; Brigitte L Kieffer
Journal:  Biol Psychiatry       Date:  2016-12-26       Impact factor: 13.382

10.  ELK1 transcription factor linked to dysregulated striatal mu opioid receptor signaling network and OPRM1 polymorphism in human heroin abusers.

Authors:  Stephanie E Sillivan; John D Whittard; Michelle M Jacobs; Yanhua Ren; Amin R Mazloom; Francesca F Caputi; Monika Horvath; Eva Keller; Avi Ma'ayan; Ying-Xian Pan; Lillian W Chiang; Yasmin L Hurd
Journal:  Biol Psychiatry       Date:  2013-05-20       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.